Healthy
Conditions
Keywords
electrocardiographic safety, pharmacokinetics
Brief summary
In this study healthy volunteers received increasing doses of prucalopride to study the tolerability and cardiac safety of prucalopride. The study hypothesis was that prucalopride at doses up to 10 mg has no clinically relevant effect on the cardiovascular safety in healthy volunteers.
Detailed description
Single-centre, double-blind, placebo-controlled, cross-over study in 33 healthy volunteers with 2 sessions. Each session consisted of a run-in day for baseline assessments, 8 treatment days and 5 additional days for followup assessments. Subjects were randomised to start with either the prucalopride or placebo session. The prucalopride dose was consecutively escalated in 2 mg steps per day, starting from 2 mg up to 10 mg once daily If a subject did not tolerate the 10- or 8-mg dose, 1 step back in the dosage scheme was allowed, from 10 to 8 mg on Day 6, or from 8 to 6 mg on Day 5. Subjects with intolerance for doses of less than 6 mg, were withdrawn from the study. Repeated dosing (6, 8 or 10 mg) was continued once daily until Day 8, to achieve steady-state. During placebo, the number of placebo tablets was consecutively escalated in an identical way as described for prucalopride. Between the 2 sessions, there was a washout period of 14 to 21 days, to avoid any carry-over effect.
Interventions
DRUGPrucalopride
OTHERPlacebo
Sponsors
Movetis
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Aged between 18 and 45 years. * Normal weight. * Healthy on the basis of a pre-study physical examination, medical history, anamnesis,ECG, 24-hour Holter monitoring, echocardiogram and the results of blood biochemistry and haematology tests and a urinalysis carried out in 3 weeks preceding randomisation.
Exclusion criteria
* History or suspicion of alcohol, barbiturate, amphetamine or narcotic abuse. * Smoking more than 10 cigarettes, or 2 cigars, or 2 pipes per day for at least 6 months prior to selection. * History of cardiac arrhythmias, bronchospastic or cardiovascular disease (e.g. ischaemic heart disease or cerebrovascular accident), diabetes mellitus, thyrotoxicosis,Parkinsonism. * Presence of prolonged QTc (Bazett) on ECG at screening (QTc \>450 ms in male subjects, QTc \>470 ms in female subjects). * Use of concomitant medication, except for oral contraceptives and paracetamol. * Participation in an investigational drug study in 30 days prior to the first visit. * Donation of blood in the 60 days preceding the first visit. * Pregnancy or breast-feeding female. * Female subjects of childbearing potential without adequate contraceptive protection during the study.
Outcome results
None listed